ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
← catalyst calendarNCT05059444 · readout ≤ 1,107 d
Sponsored by Guardant Health, Inc. (industry) · GH — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
2,020estimated
Sites
57
Countries
France, Germany, Italy +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-07 | actual | When the study began enrolling |
| Primary completion | Aug 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2021-09-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Bladder Carcinoma
- Ureter Carcinoma
- Renal Pelvis Carcinoma
- Non-small Cell Lung Cancer
- Invasive Breast Carcinoma
- Cutaneous Melanoma
- Esophageal Carcinoma
- Gastroesophageal Junction Carcinoma
- Gastric Adenocarcinoma
- Pancreatic Adenocarcinoma
- Squamous Cell Carcinoma of the Head and Neck
- Epithelial Ovarian Carcinoma
- Fallopian Tube Carcinoma
- Endometrial Carcinoma
- Renal Cell Carcinoma
- Rectal Adenocarcinoma
Intervention
- Diagnostic test: Guardant Reveal
Primary outcome
what the primary-completion date above is the date OFDistant Recurrence Free Interval (D-RFi)
measured 3 years
Permalink · GH's whole pipeline · Catalyst calendar · Every registered study · What changed